RxDoctor Payments Data

Jasmine Kirkland

Family · Douglasville, GANPI 1952821936

Payments from drug & device makers

$8,252in general payments, 2019–2025

Across 481 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$665
  • UCB, Inc.$560
  • Upsher-smith Laboratories LLC$412
  • Pfizer$395
  • Novartis$394
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$8,16599%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,252 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$24,625
Medicare patients
193
Services billed
239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$187,286
OzempicSemaglutide64$79,738
JardianceEmpagliflozin60$75,107
EliquisApixaban47$38,514
MounjaroTirzepatide26$29,165
RybelsusSemaglutide20$28,427
FarxigaDapagliflozin Propanediol23$23,912
Synjardy XrEmpagliflozin/Metformin Hcl15$17,681
Soliqua 100-33Insulin Glargine/Lixisenatide13$11,306
JanuviaSitagliptin Phosphate13$9,386
GemtesaVibegron11$7,954
SymbicortBudesonide/Formoterol Fumarate11$3,483
Gabapentin207$3,429
Rosuvastatin Calcium307$2,914
Levothyroxine Sodium310$2,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$16$187,28615 claims
Novo NordiskOzempic, Rybelsus$42$108,16584 claims
Boehringer IngelheimJardiance, Synjardy Xr$14$92,78875 claims
PfizerEliquis$395$38,51447 claims
Lilly USA, LLCMounjaro$76$29,16526 claims
AstraZenecaFarxiga, Symbicort$339$27,39534 claims
MerckJanuvia$21$9,38613 claims
Sumitomo Pharma America, Inc.Gemtesa$11$7,95411 claims
AbbVieSynthroid$1,317$1,25223 claims
ANI Pharmaceuticals, Inc.Valsartan$61$99243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →